De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Adagene Beheer

Beheer criteriumcontroles 1/4

De CEO Adagene's is Peizhi Luo, benoemd in Nov2011, heeft een ambtstermijn van 12.92 jaar. bezit rechtstreeks 3.25% van de aandelen van het bedrijf, ter waarde $ 3.20M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6 jaar en 3 jaar.

Belangrijke informatie

Peizhi Luo

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	12.9yrs
Eigendom CEO	3.3%
Management gemiddelde ambtstermijn	6yrs
Gemiddelde ambtstermijn bestuur	3yrs

Recente managementupdates

Recent updates

Adagene Inc. (NASDAQ:ADAG) Surges 26% Yet Its Low P/S Is No Reason For Excitement

Oct 10

The Consensus EPS Estimates For Adagene Inc. (NASDAQ:ADAG) Just Fell Dramatically

Oct 05

Adagene ADR GAAP EPS of -$0.87 misses by $0.45, revenue of $3.93M misses by $9.82M

Aug 30

Micro-cap Adagene surges after hours on $10M share buyback

Jun 29

CEO

Peizhi Luo (58 yo)

12.9yrs

Tenure

Dr. Peter P. Luo, PhD, also known as Peizhi, is the Founder of Adagene Inc. and serves as its Chief Executive Officer since November 2011 and Director since February 2018. He serves as President of R&D at...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Peter P. Luo	Co- Founder	12.9yrs	geen gegevens	3.25% $ 3.8m
Man Kin Tam	CFO & Director	5.1yrs	geen gegevens	geen gegevens
Jc Xu	Chief Scientific Officer	4.2yrs	geen gegevens	geen gegevens
Ami Knoefler	Vice President of Investor Relations & Corporate Communications	no data	geen gegevens	geen gegevens
Ling Zhou	Head of Human Resources	5yrs	geen gegevens	geen gegevens
Qinghai Zhao	Chief Manufacturing Officer	4yrs	geen gegevens	geen gegevens
Yan Li	Senior Vice President of Bioinformatics & Information Technology	12.9yrs	geen gegevens	geen gegevens
Xiaohong She	Senior VP & Head of Clinical Operations	12.9yrs	geen gegevens	0.094% $ 109.0k
Guizhong Liu	Senior Vice President of Early Drug Discovery	9yrs	geen gegevens	geen gegevens
Alexander Goergen	VP & Head of Business Development	7yrs	geen gegevens	geen gegevens
Jiping Zha	Executive Vice President of Clinical Development	3yrs	geen gegevens	geen gegevens
Songmao Zheng	VP and Head of Clinical & Quantitative Pharmacology	no data	geen gegevens	geen gegevens

6.0yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ADAG is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Peter P. Luo	Co- Founder	6.7yrs	geen gegevens	3.25% $ 3.8m
Man Kin Tam	CFO & Director	3.7yrs	geen gegevens	geen gegevens
Li Zhu	Independent Director	1.2yrs	geen gegevens	geen gegevens
Steven Alan Fischkoff	Member of Scientific & Strategic Advisory Board	3.2yrs	geen gegevens	geen gegevens
Robert Jay Spiegel	Member Scientific and Strategic Advisory Board	3.2yrs	geen gegevens	geen gegevens
Mervyn J. Turner	Independent Director	1.5yrs	geen gegevens	geen gegevens
Cuong Viet Do	Independent Director	1.9yrs	geen gegevens	geen gegevens
David R. Gandara	Member Scientific & Strategic Advisory Board	2.8yrs	geen gegevens	geen gegevens
Yumeng Wang	Director	1.5yrs	geen gegevens	geen gegevens
Aurelien Marabelle	Member of Scientific & Strategic Advisory Board	1.6yrs	geen gegevens	geen gegevens
Yiu Leung Cheung	Independent Director	3.7yrs	geen gegevens	geen gegevens
Stanley Frankel	Member Scientific & Strategic Advisory Board	3.2yrs	geen gegevens	geen gegevens

3.0yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ADAG wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 3 jaar), wat duidt op een nieuw bestuur.

Adagene Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Adagene Inc. Announces Board Changes

Adagene Inc. Appoints Heinz-Josef Lenz to Scientific and Strategic Advisory Board

Adagene Inc. Appoints Cuong Do to Board of Directors and Audit Committee

High number of new and inexperienced directors

High number of new and inexperienced directors

Adagene Inc. Announces Board and Management Changes

Recent updates

New minor risk - Market cap size

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$1.83 loss per share (vs US$1.85 loss in FY 2022)

Adagene Inc. Announces Board Changes

New minor risk - Financial data availability

Adagene Inc. Appoints Heinz-Josef Lenz to Scientific and Strategic Advisory Board

Adagene Inc. Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody

New major risk - Share price stability

Adagene Inc. Announces Data from its Presentation at the American Society of Clinical Oncology 2024 Gastrointestinal (GI) Cancers Symposium

Adagene Inc. Presents Data Demonstrating the Best-In-Class Therapeutic Index for Masked Anti-CTLA-4 Safebody®? Adg126

Adagene Inc. (NASDAQ:ADAG) Surges 26% Yet Its Low P/S Is No Reason For Excitement

New major risk - Revenue and earnings growth

Price target decreased by 32% to US$9.16

Full year 2022 earnings released: US$1.85 loss per share (vs US$1.83 loss in FY 2021)

Price target decreased by 9.4% to US$12.53

Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-Ctla-4 Safebody® Adg126 Up to 10 Mg/Kg with Repeat Cycles in Combination with Anti-Pd-1 Therapy from Dose Escalation Portion of Phase 1B/2 Trial

Price target increased to US$13.82

Price target decreased to US$10.78

Adagene Inc. Appoints Cuong Do to Board of Directors and Audit Committee

Price target decreased to US$12.71

High number of new and inexperienced directors

Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors

The Consensus EPS Estimates For Adagene Inc. (NASDAQ:ADAG) Just Fell Dramatically

Consensus forecasts updated

Adagene Inc. Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors

Price target increased to US$27.92

First half 2022 earnings released: US$1.09 loss per share (vs US$1.02 loss in 1H 2021)

Adagene ADR GAAP EPS of -$0.87 misses by $0.45, revenue of $3.93M misses by $9.82M

Adagene Inc. (NasdaqGM:ADAG) announces an Equity Buyback for $10 million worth of its shares.

Micro-cap Adagene surges after hours on $10M share buyback

Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody ADG126, with Repeat Dosing Across Dose Levels

High number of new and inexperienced directors

Adagene Inc. Presents Data Demonstrating First and Best-In-Class Potential for Differentiated Preclinical Antibody Candidates At American Association for Cancer Research (Aacr) Annual Meeting 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$25.69

Adagene Inc. Announces Board and Management Changes

Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116

Adagene Inc. Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1B/2 Clinical Trial of ADG106 in Combination with Nivolumab in Singapore

Adagene Announces FDA Clearance of IND for Phase 1b/2 Trial of Anti-CTLA-4 Monoclonal Antibody ADG116 in Combination Therapy with Anti-PD-1 Antibody Pembrolizumab

Director Yu Miao has left the company

Adagene Inc. Announces Clinical Data from its ADG106 NEObodyTM Program

Adagene Inc. Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126 for the Treatment of Various Advanced Solid Tumors

Adagene Inc. has completed an IPO in the amount of $139.726 million.

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd